FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL | | | | | | | | | | |
|--------------------------|-----|--|--|--|--|--|--|--|--|--|
| OMB Number: 3235-028 | | | | | | | | | | |
| Estimated average burden | | | | | | | | | | |
| hours per response: | 0.5 | | | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | | | <u>II</u> | 2. Issuer Name and Ticker or Trading Symbol IDERA PHARMACEUTICALS, INC. [IDRA] | | | | | (Ch | eck all applic Directo X Officer below) | cable) or (give title | Othe belo | Owner (specify | | |
|--|---|------------------------------|--|-------------------------------------|--|------------|---------------------------------|--|--------------------|---|---|---|--|---|---------------------------------------|--|
| C/O IDED A DUADA A CRUTEICA I C. INC | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 07/08/2021 | | | | | | SVP AND GENERAL COUNSEL | | | | | |
| 505 EAGLEVIEW BOULEVARD, SUITE 212 | | | | _ | If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | 6. Individual or Joint/Group Filing (Check Applicable | | | | | |
| (Street) | P/ | 1 | 19341 | 4. | If Ame | endment, L | Jate (| of Original File | ed (Month/Da | ay/Year) | Line | e) <mark>X</mark> Form f | led by One | Reporting Pe than One Re | son | |
| (City) | (S | tate) | (Zip) | | | | | | | | | F 61301 | | | | |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | |
| Date | | | | . Transaction ate Month/Day/Y | Execution Date, | | 3. Transaction Code (Inst | ansaction Disposed Of (D) (Instr. 3, ode (Instr. 5) | | | Beneficia | es Fe ally (E Following (I | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | | | | Code V | Amount | (A) or (D) | Price | Transact (Instr. 3 a | ion(s) | | (insti. 4) | | |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | (Month/Day/Year) e of vative | 3A. Deemed Execution Date, if any (Month/Day/Year | Code | | | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4) | Owners Form: Direct (I or Indirect (I) (Instr | Beneficial Ownership (Instr. 4) | |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | | |
| Stock Option (Right to Buy) | \$1.11 | 07/08/2021 | | A | | 66,500 | | (1) | 07/08/2031 | Common Stock | 66,500 | \$0 | 66,500 | D | | |

Explanation of Responses:

1. The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on July 8, 2021. Twenty-five percent (25%) of the stock option vests and becomes exercisable on July 8, 2022 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.

/s/ Bryant D. Lim

07/12/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.